Home › NDC Lookup › RxCUI directory › RxCUI 197626

Doxazosin 2 MG Oral Tablet — RxCUI 197626

RxNorm drug concept · Semantic clinical drug
RxCUI 197626 Semantic clinical drug · SCD ● Current RxNorm concept 95 FDA products 161 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI197626
Official nameDoxazosin 2 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdoxazosin (as doxazosin mesylate) 2 MG Oral Tablet; doxazosin mesylate 2 MG Oral Tablet
FDA products mapped95
Package NDCs mapped161
Reported Medicaid activity (SDUD)163,813 prescriptions · 49 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Doxazosin: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yes, if you're taking the tablet form (like Cardura or generic doxazosin tablets), it can help with both conditions at once. The medication relaxes smooth muscle in the prostate ar...
  • Can doxazosin treat both my enlarged prostate and my high blood pressure at the same time?
  • That dizziness is a known side effect called postural hypotension — your blood pressure dips when you change positions. It's most common after your first dose or after a dose incre...
  • I feel dizzy when I stand up after taking doxazosin. Is that normal, and what should I do?
📖 Read our full Doxazosin guide →

🕸️ Concept Web — How Doxazosin 2 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Doxazosin 2 MG Oral Tablet RxCUI 197626

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Doxazosin 49276
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Cardura 196468
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Doxazosin Oral Tablet 371961
    • Doxazosin Oral Product 1160764
    • Doxazosin Pill 1160765
    • Doxazosin Oral Tablet [Cardura] 92084
    • Cardura Oral Product 1175764
    • Cardura Pill 1175765
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Doxazosin 2 MG SCDC · 328236
  • Doxazosin Oral Tablet SCDF · 371961
  • Doxazosin Oral Product SCDG · 1160764
  • Doxazosin Pill SCDG · 1160765

Brand-Name Concepts

  • Doxazosin 2 MG Oral Tablet [Cardura] SBD · 104368
  • Doxazosin 2 MG [Cardura] SBDC · 563607
  • Doxazosin Oral Tablet [Cardura] SBDF · 92084
  • Cardura Oral Product SBDG · 1175764
  • Cardura Pill SBDG · 1175765
  • Cardura BN · 196468

📦 FDA Products & Package NDCs

95 products · 161 package NDCs
161 package NDCs map to RxCUI 197626 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
71335-3081-04 28 TABLET in 1 BOTTLE (71335-3081-4) Doxazosin Bryant Ranch Prepack 2026-02-13
71335-3081-05 18 TABLET in 1 BOTTLE (71335-3081-5) Doxazosin Bryant Ranch Prepack 2026-02-13
71610-0153-60 90 TABLET in 1 BOTTLE (71610-153-60) Doxazosin Aphena Pharma Solutions - Tennessee, LLC 2018-09-18
71610-0160-16 6000 TABLET in 1 BOTTLE (71610-160-16) Doxazosin Aphena Pharma Solutions - Tennessee, LLC 2018-09-20
71610-0160-60 90 TABLET in 1 BOTTLE (71610-160-60) Doxazosin Aphena Pharma Solutions - Tennessee, LLC 2021-11-23
71610-0482-60 90 TABLET in 1 BOTTLE (71610-482-60) Doxazosin Aphena Pharma Solutions - Tennessee, LLC 2020-11-10
72189-0117-60 60 TABLET in 1 BOTTLE (72189-117-60) DOXAZOSIN direct rx 2020-12-02
84677-0044-01 100 TABLET in 1 BOTTLE (84677-044-01) Doxazosin Golden State Medical Supply, Inc. 2026-05-11
84677-0045-01 100 TABLET in 1 BOTTLE (84677-045-01) Doxazosin Golden State Medical Supply, Inc. 2026-05-11
84677-0046-01 100 TABLET in 1 BOTTLE (84677-046-01) Doxazosin Golden State Medical Supply, Inc. 2026-05-11
84677-0047-01 100 TABLET in 1 BOTTLE (84677-047-01) Doxazosin Golden State Medical Supply, Inc. 2026-05-11
Observed labelers: Zydus Lifesciences Limited (16) · Zydus Pharmaceuticals USA Inc. (16) · Bryant Ranch Prepack (15) · Unichem Pharmaceuticals (USA), Inc. (12) · Accord Healthcare Inc. (8) · Apotex Corp. (8) · +23 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.